Last reviewed · How we verify
Ubrelvy (UBROGEPANT)
Ubrelvy blocks the action of a molecule called calcitonin gene-related peptide, which is involved in migraine pain.
Ubrelvy (ubrogepant) is a calcitonin gene-related peptide receptor antagonist, a small molecule developed by Allergan and currently owned by Abbvie. It targets the calcitonin gene-related peptide type 1 receptor to treat migraine. Ubrelvy was FDA-approved in 2019 for this indication and remains a patented product with no generic manufacturers. Key safety considerations include potential liver enzyme elevations and interactions with other medications. As a calcitonin gene-related peptide receptor antagonist, Ubrelvy works by blocking the action of a key molecule involved in migraine pain.
At a glance
| Generic name | UBROGEPANT |
|---|---|
| Sponsor | AbbVie |
| Drug class | Calcitonin Gene-related Peptide Receptor Antagonist [EPC] |
| Target | Calcitonin gene-related peptide type 1 receptor |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2019 |
| Annual revenue | 664 |
Mechanism of action
Ubrogepant is calcitonin gene-related peptide receptor antagonist.
Approved indications
- Migraine
Common side effects
- Nausea
- Somnolence
- Dry Mouth
Key clinical trials
- Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada
- Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) (PHASE3)
- Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
- An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants
- Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy
- Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine (PHASE3)
- A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine (PHASE1)
- Migraine Medication Effects on Urinary Symptoms
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ubrelvy CI brief — competitive landscape report
- Ubrelvy updates RSS · CI watch RSS
- AbbVie portfolio CI